Stockscreener 앱 받기
0.263
0.44%
-0.007
전일 마감가:
$0.27
열려 있는:
$0.255
하루 거래량:
158.54K
Relative Volume:
0.07
시가총액:
$15.99M
수익:
-
순이익/손실:
$-41.95M
주가수익비율:
-0.3169
EPS:
-0.83
순현금흐름:
$-38.34M
1주 성능:
+7.52%
1개월 성능:
-45.60%
6개월 성능:
-47.55%
1년 성능:
-94.56%
1일 변동 폭
$0.255
$0.27
1주일 범위
$0.221
$0.274
52주 변동 폭
$0.221
$4.92
Elevation Oncology Inc Stock (ELEV) Company Profile
명칭
Elevation Oncology Inc
전화
(716) 371-1125
주소
101 FEDERAL STREET, BOSTON
ELEV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.2643 | 15.99M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.54 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.54 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
585.97 | 35.29B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.14 | 29.62B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.21 | 22.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-24 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2025-03-21 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-03-21 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-05-30 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2021-12-23 | 개시 | H.C. Wainwright | Buy |
모두보기
Elevation Oncology Inc 주식(ELEV)의 최신 뉴스
Fierce Biotech Layoff Tracker 2025: Opthea reduces workforce by 65%; Organon lays off 93 staffers - Fierce Biotech
Elevation Oncology opts for early term loan repayment By Investing.com - Investing.com South Africa
Elevation Oncology opts for early term loan repayment - Investing.com
Elevation Oncology IncTo Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022SEC Filing - MarketScreener
Virtu Financial LLC Takes $36,000 Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology’s Chief Medical Officer Steps Down - TipRanks
What is Elevation Oncology Inc (ELEV) Stock Return on Shareholders’ Capital? - Sete News
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Breakthrough Cancer Drug Shows Promise: First Look at EO-1022 Data for Breast and Lung Cancer - Stock Titan
Elevation Oncology (NASDAQ:ELEV) Given “Equal Weight” Rating at Stephens - Defense World
Analysts Set Expectations for ELEV FY2029 Earnings - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Neutral” at Piper Sandler - The AM Reporter
Massachusetts-Based Elevation Oncology Cuts 70% of Workforce After Drug Setback - NewsBreak: Local News & Alerts
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to “Market Perform” at Citizens Jmp - Defense World
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to Neutral at Piper Sandler - Defense World
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to Market Perform at Leerink Partners - Defense World
HC Wainwright Lowers Elevation Oncology (NASDAQ:ELEV) Price Target to $1.00 - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Hold” at Leerink Partnrs - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to Hold at Wedbush - Defense World
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $6.83 Average Target Price from Analysts - Defense World
Elevation Oncology Plunges 42% on Ending Development of Lead Drug - MSN
Elevation Oncology stock rating cut amid ADC asset halt By Investing.com - Investing.com Canada
Elevation Oncology Plunges 42% On Ending Development Of Lead Drug - Barchart
Boston cancer biotech cuts 70% of staff - The Business Journals
Elevation Oncology downgraded as it halts lead asset on disappointing trials - Yahoo Finance
Tesla To $410? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Piper Sandler Downgrades Elevation Oncology to Neutral From Overweight, Adjusts Price Target to $0.70 From $10 - Marketscreener.com
Piper Sandler cuts Elevation Oncology stock rating to Neutral By Investing.com - Investing.com Canada
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70% - Benzinga
Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding - Endpoints News
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results - Benzinga
Elevation Oncology, Inc. Implements A Workforce Reduction of Approximately 70% -March 20, 2025 at 08:08 am EDT - Marketscreener.com
Elevation Oncology halts development of cancer drug EO-3021 By Investing.com - Investing.com Australia
Sector Update: Health Care Stocks Decline Pre-Bell Thursday - TradingView
Elevation Oncology tumbles after halting development of cancer drug - TradingView
Elevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell - Marketscreener.com
Why Is Elevation Oncology Stock Falling In Pre-market? - Nasdaq
Elevation Oncology stock tumbles on halted drug development By Investing.com - Investing.com Canada
Elevation Oncology Restructures Amid EO-3021 Discontinuation - TipRanks
Elevation Oncology stock tumbles on halted drug development - Investing.com India
Elevation Oncology halts development of cancer drug EO-3021 - Investing.com India
Elevation Oncology Halts Cancer Drug Development, Slashes Jobs in Major Strategic Shift - StockTitan
Elevation Oncology shifts to Nasdaq Capital Market By Investing.com - Investing.com Australia
Elevation Oncology shifts to Nasdaq Capital Market - Investing.com India
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
HC Wainwright Has Optimistic Outlook of ELEV Q1 Earnings - Defense World
Elevation Oncology Inc (ELEV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.44%
0.27%
자본화:
|
볼륨(24시간):